{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:14:55Z","timestamp":1774469695807,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":449,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,10]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The pharmacologic profile of the new proton pump inhibitor esomeprazole has demonstrated advantages over omeprazole that suggest clinical benefits for patients with acid\u2010related disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>1960 patients with endoscopy\u2010confirmed reflux oesophagitis (RO) were randomized to once daily esomeprazole 40\u2003mg (<jats:italic>n<\/jats:italic>=654) or 20\u2003mg (<jats:italic>n<\/jats:italic>=656), or omeprazole 20\u2003mg (<jats:italic>n<\/jats:italic>=650), the standard recommended dose for RO, for up to 8\u2003weeks in a US, multicentre, double\u2010blind trial. The primary efficacy variable was the proportion of patients healed at week 8. Secondary variables included healing and heartburn resolution at week 4, time to first resolution and sustained resolution of heartburn, and per cent of heartburn\u2010free days and nights. Safety and tolerability were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Significantly more patients were healed at week 8 with esomeprazole 40\u2003mg (94.1%) and 20\u2003mg (89.9%) vs. omeprazole 20\u2003mg (86.9%), using cumulative life table estimates, ITT analysis (each <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Esomeprazole 40\u2003mg was also significantly more effective than omeprazole for healing at week 4 and for all secondary variables evaluating heartburn resolution. The most common adverse events in all treatment groups were headache, abdominal pain and diarrhoea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Esomeprazole was more effective than omeprazole in healing and symptom resolution in GERD patients with reflux oesophagitis, and had a tolerability profile comparable to that of omeprazole.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00856.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:40:29Z","timestamp":1047354029000},"page":"1249-1258","source":"Crossref","is-referenced-by-count":283,"title":["Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial"],"prefix":"10.1111","volume":"14","author":[{"given":"P. J.","family":"Kahrilas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. W.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. W.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Whipple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hamelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Joelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"FOR THE ESOMEPRAZOLE STUDY INVESTIGATORS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"National Institutes of Health National Digestive Diseases Information Clearinghouse. Gastroesophageal reflux disease (Hiatal hernia and heartburn): <http:\/\/www.niddk.nih.gov\/health\/digest\/pubs\/heartbrn\/heartbrn.htm>. Accessed 14 May1999."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61790-X"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001574-199807000-00011"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","article-title":"The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts","volume":"12","author":"Thomson AB","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_7_6_2","first-page":"90","article-title":"Medical treatment of gastroesophageal reflux in the managed care environment","volume":"8","author":"Fennerty M","year":"1997","journal-title":"Semin Gastrointest Dis"},{"key":"e_1_2_7_7_2","first-page":"126","article-title":"The economics of therapy of gastroesophageal reflux disease","volume":"10","author":"Fennerty M","year":"1997","journal-title":"Gastroenterol Int"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309098350"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200911"},{"key":"e_1_2_7_10_2","first-page":"3S","article-title":"The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure","volume":"92","author":"Orlando RC","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_11_2","first-page":"497","article-title":"Are esophageal symptoms reflux\u2010related? A study of different scoring systems in a cohort of patients with heartburn","volume":"89","author":"Johnston BT","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90847-X"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.5.649"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528609011128"},{"key":"e_1_2_7_15_2","first-page":"649","article-title":"Progress with proton pump inhibition","volume":"65","author":"Bell NJ","year":"1992","journal-title":"Yale J Biol Med"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448010-00008"},{"key":"e_1_2_7_17_2","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba N","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2008.S1"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91790-B"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178669"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00002"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.44186000.x"},{"key":"e_1_2_7_24_2","unstructured":"AnderssonT R\u00f6hssK HassanpAlinM BredbergE.Pharmacokinetics and Dose\u2013response Relationship of Esomeprazole. Abstracts of the Joint Meeting of the 7th World Confederation on Clinical Pharmacy and Therapeutics (IUPHAR) Division of Clinical Pharmacology and 4th World Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT)."},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00813.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.172"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(99)70285-3"},{"key":"e_1_2_7_28_2","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group","volume":"91","author":"Castell DO","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.56198000.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309096076"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199611000-00013"},{"key":"e_1_2_7_32_2","first-page":"A39","article-title":"A comparison of omeprazole MUPS 20 MG, Lansoprazole 30 mg and pantoprazole 40 mg in the treatment of reflux oesophagitis: a multicenter trial","volume":"45","author":"Mulder CJJ","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_33_2","first-page":"A177","article-title":"Are there any differences in symptom relief and healing esophagitis between proton pump inhibitors (PPIs): a meta\u2010analysis of comparative trials","volume":"45","author":"Huang JQ","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00438.x"},{"key":"e_1_2_7_35_2","first-page":"A41","article-title":"Rabeprazole is comparable in efficacy to omeprazole in erosive GERD and provides more rapid heartburn relief","volume":"45","author":"Delchier JC","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_36_2","first-page":"A178","article-title":"Rabeprazole is as effective as omeprazole in preventing relapse of erosive or ulcerative GERD in the second year of treatment","volume":"45","author":"Thjodleifsson B","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00437.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00388.x"},{"key":"e_1_2_7_39_2","first-page":"A265","article-title":"Pantoprazole (PANTO) 20 mg is as effective as omeprazole (OME) 20 mg in patients with mild gastroesophageal reflux disease (GERD)","volume":"45","author":"Bardhan KD","year":"1999","journal-title":"Gut"},{"key":"e_1_2_7_40_2","first-page":"A77","article-title":"Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis","volume":"110","author":"Carlsson R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00669.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00856.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00856.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00856.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T16:52:35Z","timestamp":1698598355000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00856.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00856.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00856.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}